OSE Immunotherapeutics SA (EPA:OSE)
France · Delayed Price · Currency is EUR 3.394
-0.024 (-0.70%)
Jun 23, 2026, 5:35 PM CET
OSE Immunotherapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2.62 | 69.88 | 2.23 | 18.3 | 26.31 |
Other Revenue | 0.07 | 13.56 | - | - | - |
| 2.69 | 83.44 | 2.23 | 18.3 | 26.31 | |
Revenue Growth (YoY) | -96.78% | 3646.52% | -87.83% | -30.43% | 152.48% |
Cost of Revenue | 0.3 | 0.34 | - | - | - |
Gross Profit | 2.39 | 83.09 | 2.23 | 18.3 | 26.31 |
Selling, General & Admin | 8.14 | 5.92 | 5.96 | 6.59 | 8.5 |
Research & Development | 33.93 | 30.45 | 17.09 | 26.82 | 30.49 |
Other Operating Expenses | -4.12 | 0.27 | 0.13 | 0.24 | 0.16 |
Operating Expenses | 39.87 | 39.36 | 25.21 | 36.78 | 42.93 |
Operating Income | -37.49 | 43.74 | -22.99 | -18.48 | -16.63 |
Interest Expense | -2.82 | -3.17 | -2.2 | -1.37 | -0.84 |
Interest & Investment Income | 0.79 | 1.47 | 0.34 | 0.02 | 0.01 |
Currency Exchange Gain (Loss) | 0.01 | -0.02 | -0.04 | -0 | 0.04 |
Other Non Operating Income (Expenses) | 1.87 | -2.41 | 1.66 | 1.82 | 0.2 |
EBT Excluding Unusual Items | -37.63 | 39.6 | -23.23 | -18.02 | -17.22 |
Gain (Loss) on Sale of Investments | 0.22 | 0.23 | 0 | - | 0 |
Pretax Income | -37.41 | 39.83 | -23.22 | -18.02 | -17.21 |
Income Tax Expense | 0.28 | 2.39 | -0.22 | -0.26 | -0.36 |
Net Income | -37.69 | 37.45 | -23 | -17.76 | -16.85 |
Net Income to Common | -37.69 | 37.45 | -23 | -17.76 | -16.85 |
Shares Outstanding (Basic) | 22 | 22 | 20 | 19 | 18 |
Shares Outstanding (Diluted) | 22 | 26 | 20 | 19 | 18 |
Shares Change (YoY) | -13.10% | 31.11% | 5.58% | 2.05% | 16.71% |
EPS (Basic) | -1.69 | 1.72 | -1.18 | -0.96 | -0.93 |
EPS (Diluted) | -1.69 | 1.46 | -1.18 | -0.96 | -0.93 |
Free Cash Flow | -34.13 | 48.36 | -19.78 | -18.53 | -10.39 |
Free Cash Flow Per Share | -1.53 | 1.89 | -1.01 | -1.00 | -0.57 |
Gross Margin | 88.70% | 99.59% | 100.00% | 100.00% | 100.00% |
Operating Margin | -1392.98% | 52.42% | -1032.15% | -100.96% | -63.20% |
Profit Margin | -1400.56% | 44.88% | -1032.91% | -97.04% | -64.05% |
Free Cash Flow Margin | -1268.38% | 57.97% | -888.19% | -101.22% | -39.50% |
EBITDA | -37.33 | 46.31 | -20.31 | -15.68 | -14.66 |
EBITDA Margin | - | 55.51% | - | -85.69% | -55.71% |
D&A For EBITDA | 0.15 | 2.58 | 2.68 | 2.8 | 1.97 |
EBIT | -37.49 | 43.74 | -22.99 | -18.48 | -16.63 |
EBIT Margin | - | 52.42% | - | -100.96% | -63.20% |
Effective Tax Rate | - | 5.99% | - | - | - |
Revenue as Reported | - | - | - | 18.3 | 26.31 |
Advertising Expenses | 0.1 | 0.4 | - | - | - |